Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

[1]  Sihai Zhao,et al.  The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits. , 2008, Thrombosis research.

[2]  A. Chait,et al.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies , 2008, The Lancet.

[3]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[4]  M. Bots,et al.  Measurement of carotid intima–media thickness to assess progression and regression of atherosclerosis , 2008, Nature Clinical Practice Cardiovascular Medicine.

[5]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[6]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[7]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[8]  K. Wolski,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[9]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[10]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[11]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[12]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[13]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[14]  J. Staessen,et al.  Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials , 2006, Stroke.

[15]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[16]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[17]  J. O’Keefe,et al.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. , 2005, Journal of the American College of Cardiology.

[18]  B. Staels,et al.  Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.

[19]  T. Forst,et al.  Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study , 2005, Circulation.

[20]  H. Markus,et al.  Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Diederick E Grobbee,et al.  Carotid Intima-Media Thickness Measurements in Intervention Studies: Design Options, Progression Rates, and Sample Size Considerations: A Point of View , 2003, Stroke.

[22]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[23]  E. Lonn,et al.  Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report , 2002, Cardiovascular Drugs and Therapy.

[24]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  S. Yusuf,et al.  Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.

[26]  S. Jacob,et al.  ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[28]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.